LEUKEMIA & LYMPHOMA SOCIETY INC LEXINGTON CHAPTER
836 Euclid Avenue
Suite 317
Lexington KY 40502-5223
Contact Information
Nonprofit LEUKEMIA & LYMPHOMA SOCIETY INC LEXINGTON CHAPTER
Address 836 Euclid Avenue
Suite 317
Lexington, KY 40502 5223
Phone (502) 719-0544
Fax 502 589-5316
Contact Name Hannah Hardesty
At A Glance
IRS Ruling Year 2001
Former Names
Leukemia Society of America
Other ways to donate, support, or volunteer
Interested donors can mail checks to:  836 Euclid Ave, #317 / Lexington, KY 40502.
If interested in volunteering for events, office work, or donating in-kind items, please call:  502.584.8490
 
Financial Summary
Revenue vs Expenses - All Years
Expense Breakdown - Recent Year
Statements
Mission Statement The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to treatments for blood cancer patients. Today, LLS is the world’s largest voluntary health agency dedicated to finding cures for leukemia, lymphoma, myeloma and other blood cancers.
Background Statement The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS is the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Our Key Priorities will ensure that:The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives. Research * Advance the diagnosis and treatment of blood cancers through continued funding of academic research, the therapy acceleration program and other special initiatives * Proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma & myeloma * Participate directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists Patient Services * Develop a services agenda for patients and their families to address their information and support needs * Inform blood cancer patients and improve access to the latest individual therapy options and blood cancer clinical trials * LLS is the key source of information and services for patients throughout their cancer journey Public Policy * Increase funding from non-LLS sources to accelerate the discovery and development of blood cancer therapies * Encourage an effective and science-driven regulatory system for efficient review of new blood cancer therapies * Ensure patients have insurance coverage for their treatments and well-coordinated and high quality cancer care
Impact Statement As of 2014, LLS has invested nearly $1 billion in research to advance therapies and save lives. From 2000 through 2013, almost 40 percent (31 of 81) of new anti-cancer drugs were FDA-approved for blood cancer patients, more first-ever approvals than for any other group of cancers, and many of these were advanced with funding from LLS. Many of these therapies are also helping patients with other cancers and other serious diseases. LLS is the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals. In North America, LLS’s co-pay assistance program has raised more than $200 million to date to help eligible blood cancer patients afford health-insurance premiums and prescription drug co-pays, assisting more than 36,000 patients since its inception in 2007. LLS also advocates for policies at the federal and state levels to accelerate the approval of new treatments and ensure access to quality, affordable and coordinated care.
Needs Statement


CEO/Executive Director Statement
 
Board Chair Statement
 
Geographic Areas Served
Areas
Throughout the United States
Kentucky
LLS impacts patients and their families through their 61 chapters across the United States and Canada. The KY Chapter serves 117 counties across the Bluegrass State.   
Board Chair
Board Chair Ms. Diahanna Vallentine
Company Affiliation Allen Financial Group
Term July 2017 to June 2018
Board Members
NameAffiliationStatus
Dave Brown Brown-Forman
Mindy Brown Celgene
Jason Cox Walgreens
Marty Driskell UPSVoting
Leslie Hurst Walgreens
Dr Geetha Joseph Baptist Hospital & CBCVoting
Ben Keeton Medical News
John King King Southern Bank
Aimee McCaa Norton HealthcareVoting
Dr. Chandler Park UofL
Joe Peters Galen Nurshing
Mark Robinson Anthem
Jennifer Washle Bisig Impact GroupVoting
Board Demographics - Ethnicity
African American/Black 2
Asian American/Pacific Islander 0
Caucasian 5
Hispanic/Latino 1
Native American/American Indian 1
Other 0 0
Board Demographics - Gender
Male 3
Female 6
Unspecified 0
Governance
Board Term Lengths 3
Board Term Limits 3
Board Meeting Attendance % 84%
Written Board Selection Criteria? Under Development
Written Conflict of Interest Policy? Yes
Percentage Making Monetary Contributions 100%
Percentage Making In-Kind Contributions 100%
Constituency Includes Client Representation Yes
Number of Full Board Meetings Annually 6
Board Co-Chair
Board CoChair Vallentine
CEO/Executive Director
Executive Director Mrs. Helen Overfield
Term Start Mar 2016
Email helen.overfield@lls.org
Staff
Full Time Staff 4
Part Time Staff 5
Volunteers 700
Contractors 0
Retention Rate 80%
Staff Demographics - Ethnicity
African American/Black 1
Asian American/Pacific Islander 0
Caucasian 8
Hispanic/Latino 0
Native American/American Indian 0
Other 0 1
Staff Demographics - Gender
Male 2
Female 8
Unspecified 0
Formal Evaluations
CEO Formal Evaluation Yes
CEO/Executive Formal Evaluation Frequency Annually
Senior Management Formal Evaluation Yes
Senior Management Formal Evaluation Frequency Annually
NonManagement Formal Evaluation Yes
Non Management Formal Evaluation Frequency Annually
Description The Leukemia & Lymphoma Society's Light The Night Walk funds treatments that are saving the lives of patients today. LLS is making cures happen by providing patient support services, advocating for lifesaving treatments and pioneering the most promising cancer research anywhere. And it's all happening now. Not someday, but today. Each year friends, families and co workers form teams to raise money in support of our mission.
Budget 30,000
Category Health Care, General/Other Chemotherapy/Radiation
Population Served People/Families of People with Cancer, ,
Plans & Policies
Organization has a Fundraising Plan? Under Development
Organization has a Strategic Plan?
Management Succession Plan? No
Organization Policy and Procedures Yes
Nondiscrimination Policy Yes
Whistleblower Policy Yes
Document Destruction Policy Yes
Financials
Revenue vs Expenses - All Years
Expense Breakdown - Recent Year
Fiscal Year
Fiscal Year Start July 30, 2017
Fiscal Year End June 01, 2018
Projected Revenue $1,524,051.00
Projected Expenses $824,395.00
Spending Policy N/A
Detailed Financials
Expense Allocation
Fiscal Year201620152014
Program Expense$414,437--$947,913
Administration Expense$81,817--$174,746
Fundraising Expense$110,303--$199,599
Payments to Affiliates------
Total Revenue/Total Expenses1.93--1.02
Program Expense/Total Expenses68%--72%
Fundraising Expense/Contributed Revenue9%--15%
Assets and Liabilities
Fiscal Year201620152014
Total Assets$47,875--$33,136
Current Assets$29,934--$29,956
Long-Term Liabilities$47,875----
Current Liabilities$25,428--$138,609
Total Net Assets$22,447--($105,473)
Capital Campaign
Currently in a Capital Campaign? No
State Registration Yes
Comments
Foundation Staff Comments

This organization is under the charitable umbrella of the national organization, the Leukemia & Lymphoma Society. The Leukemia & Lymphoma Society Lexington Chapter's financials are included the national organization's 990s.

Address 836 Euclid Avenue
Suite 317
Lexington, KY 405025223
Primary Phone 502 719-0544
Contact Email helen.overfield@lls.org
CEO/Executive Director Mrs. Helen Overfield
Board Chair Ms. Diahanna Vallentine
Board Chair Company Affiliation Allen Financial Group